HCV confirmatory testing of blood donors

Boudart, D.; Lucas, J.; Adjou, Chantal; Muller, Jean‐Yves

doi:10.1016/0140-6736(92)91695-5

Cited by 25 publications

(6 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The present data confirm the previous suggestion [3][4][5][6] that most of the observed core-indeterminate sera are attributable to false-positive reactions with the recombinant core antigen (C22-3 or equivalent). The use of synthetic peptides (in RIBA-3 or Monolisa anti-HCV, new antigens) or more strictly de fined recombinant protein fragments (in house antigen) of the core region appeared elucidive for discrimination.…”

supporting

confidence: 81%

New Tools for HCV Confirmation

Claeys¹,

Verhaert²,

Zhong³

et al. 1995

Vox Sanguinis

View full text Add to dashboard Cite

supporting

confidence: 81%

New Tools for HCV Confirmation

Claeys¹,

Verhaert²,

Zhong³

et al. 1995

Vox Sanguinis

View full text Add to dashboard Cite

“…Since the introduction of a second-generation anti-HCV antibody enzyme immunoassays, the sensitivity for diagnosing HCV infection has increased significantly [McHutchison et al, 1992;Jeffers et al, 19921, and the specificity has been improved by the development of confirmatory tests such as RIBA2 [Boudart et al, 1992;Follet et al, 1991;van der Poel et al, 19911. This assay has recombinant antigens from the core region and the nonstructural (NS) regions (NS3 and NS4).…”

Section: Introductionmentioning

confidence: 99%

Nucleotide sequences of the hepatitis C virus core region in patients without anti-core antibody

Nagasaka¹,

Hige²,

Kurosawa³

et al. 1996

J. Med. Virol.

View full text Add to dashboard Cite

Second-generation assays for detection of hepatitis C virus (HCV) infection that include reactivity of antibodies to core, NS3, NS4 are used because of their high sensitivity. Among these antibodies, anti-core antibody seems to be the most sensitive. However, there are some patients without anti-core antibodies, although HCV RNA is detectable by reverse transcription-polymerase chain reaction and branched DNA assay. The mechanism for the absence of anti-core antibody on its own is unclear. We therefore determined the nucleotide and deduced amino acid sequences of the core region obtained from two anti-core antibody-negative patients with HCV RNA (genotype 1b) and compared them with those of four anti-core antibody-positive patients and a previously reported sequence. Amino acids spanning 1-47, which seemed to exist in major B cell epitopes, were found to be completely conserved among these patients. Furthermore, the predictive binding motif to HLA DR4 (a.a 81-90) was completely conserved in both of the anti-core antibody-negative patients. There were various mutations in the residual amino acids spanning 49-108, but specific mutations could not be found in anti-core antibody-negative patients. These data indicate that the absence of anti-core antibody in two patients is not due to the presence of some formerly unknown viral variants, but due to a possible defect in the host's immune system.

show abstract

“…However, it is clear from a number of studies that the C100-3 EIA generated significant numbers of both false-positive and false-negative results , the latter being particularly common among donors without elevated levels of ALT. To ameliorate these problems, second-and thirdgeneration serological tests that include additional structural and nonstructural protein or peptide epitopes are currently being evaluated in both screening and supplemental (confirmatory) assays (10)(11)(12)(13)(14)(15)(16). These tests, like the first-generation test, rely on the detection of an antibody response to viral antigens.…”

mentioning

confidence: 99%

Analysis of hepatitis C virus RNA prevalence and surrogate markers of infection among seropositive voluntary blood donors

et al. 1993

View full text Add to dashboard Cite

A novel reverse transcription polymerase chain reaction assay has been developed that uses drop-in-drop-out primers for the heminested amplification of hepatitis C virus complementary DNA. This assay has been used for analysis of the prevalence of hepatitis C virus RNA in a set of 53 plasma specimens from blood donations that were repeatedly reactive for hepatitis C virus antibodies with the first-generation enzyme immunoassay. Of 21 specimens that were also reactive for hepatitis C virus antibodies by a four-antigen recombinant immunoblot assay (recombinant immunoblot assay 2), 20 (95%) contained detectable levels of hepatitis C virus RNA. Cryoprecipitate in three specimens reactive in the recombinant immunoblot assay led to an apparent failure of detecting hepatitis C virus RNA, but repeat tests of redissolved cryoprecipitate subsequently revealed hepatitis C virus RNA. Hepatitis C virus RNA was also detected in plasma from 5 of 29 donors nonreactive by recombinant immunoblot assay. However, evidence of viremia in these donors could not be confirmed on follow-up specimens collected more than 1 yr later. Our results demonstrate that the presence of recombinant immunoblot assay reactivity nearly always indicates hepatitis C viremia and suggest that viremia may be transient or fluctuating among some individuals who are nonreactive for hepatitis C virus antibodies by the recombinant immunoblot assay.

show abstract

HCV confirmatory testing of blood donors

Cited by 25 publications

References 0 publications

New Tools for HCV Confirmation

New Tools for HCV Confirmation

Nucleotide sequences of the hepatitis C virus core region in patients without anti-core antibody

Analysis of hepatitis C virus RNA prevalence and surrogate markers of infection among seropositive voluntary blood donors

Contact Info

Product

Resources

About